At a glance
- Perform antifungal susceptibility testing for C. auris following Infectious Disease Society of America (IDSA) guidelines.
- The Clinical and Laboratory Standards Institute (CLSI) does not have defined breakpoints for C. auris.
- CDC established tentative breakpoints based on expert opinion and breakpoints established for closely related species.
Current breakpoint guidelines
The Clinical and Laboratory Standards Institute (CLSI) establishes guidelines for antifungal susceptibility testing. Those guidelines provide recommendations for determining the susceptibility of different fungi to different antifungal drugs.
There is currently only an established C. auris-specific susceptibility breakpoint for rezafungin (susceptibility data is found in CLSI document M27SM44S). Tentative C. auris breakpoints are based on expert opinion and established breakpoints for closely related Candida species. Correlation between these tentative breakpoints and clinical outcomes is not known at this time. The information below should serve as a general guide and not as definitive breakpoints for resistance.
Antifungal susceptibility testing guidelines
| Triazole Class Drugs | Tentative MIC Breakpoints (µg/mL) | Comment |
|---|---|---|
| Fluconazole | ≥32 | Modal minimum inhibitory concentration (MIC) to fluconazole among isolates tested at CDC was ≥256; isolates with MICs ≥32 were shown to have a resistance mutation in the Erg11 gene, making them unlikely to respond to fluconazole. |
| Voriconazole and other second generation triazoles | N/A | Consider using fluconazole susceptibility as a surrogate for second generation triazole susceptibility assessment. However, isolates that are resistant to fluconazole may respond to other triazoles occasionally. The decision to treat with another triazole will need to be made on case-by-case basis. |
| Polyene Class Drug | Tentative MIC Breakpoints (µg/mL) | Comment |
|---|---|---|
| Amphotericin B | ≥2 | Recent pharmacokinetic/pharmacodynamic analysis of C. auris in a mouse model of infection indicates that under standard dosing, the breakpoint for amphotericin B should be 1 or 1.5, similar to what has been determined for other Candida species. Therefore, isolates with an MIC of ≥2 should now be considered resistant. If using Etest for amphotericin B and an MIC of 1.5 is determined, that value should be rounded up to 2. |
| Echinocandin Class Drugs | Tentative MIC Breakpoints (µg/mL) | Comment |
|---|---|---|
| Anidulafungin | ≥ 4 | Tentative breakpoints are based on the modal distribution of echinocandin MICs of approximately 100 isolates from diverse geographic locations. |
| Caspofungin | ≥ 2 | |
| Micafungin | ≥ 4 |
Resistance to multiple classes of drugs
Please note that a finding of an elevated minimum inhibitory concentration (MIC) for an antifungal drug should not necessarily preclude its use. This is especially true if the use of other antifungal drugs for the patient has been ineffective.
Based on these MIC breakpoints, many isolates are resistant to multiple classes of drugs. Some U.S. C. auris isolates have been found to be resistant to all three classes of antifungal drugs. CDC has received reports of pan-resistance found in other countries as well.
This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.
The information on this page was last reviewed by subject matter experts to ensure accuracy.